New study to further improve CAR T-cell therapy
10 augustus 2026
A new international clinical trial aims to further improve CAR T-cell immunotherapy for children with acute lymphoblastic leukemia (ALL). The first child at the Princess Máxima Center is now being treated as part of the INFLUENCE trial. The researchers are investigating whether personalized pre-treatment can ensure that CAR T-cells do their job better and for longer.
CAR T-cell therapy is a form of immunotherapy for children with ALL whose leukemia comes back, or for whom standard treatment does not work well enough. In this therapy, the child's T-cells, a specific type of immune cell, are modified outside the body so that they can recognize and destroy leukemia cells.
Further increasing success
‘In recent years, we have seen that CAR T-cell therapy can be very effective for some children with ALL,’ says pediatric oncologist Dr. Friso Calkoen, who leads the European part of the study. ‘But unfortunately, the treatment does not work sufficiently for every child. With this study, we aim to investigate how we can further increase the success of this therapy.’
Personalized fludarabine dose
Before a child receives CAR T-cells, the immune system is temporarily suppressed with fludarabine, a form of chemotherapy. This gives the CAR T-cells room to grow. In the new study, half of the children will get the standard dose of fludarabine. The other half will get a personalized, higher dose. This allows researchers to see whether the CAR T-treatment works better and for longer afterwards.
The entire European part of the study is made possible by a grant from KiKa. The INFLUENCE study is led in Europe by the Princess Máxima Center and in the United States by Memorial Sloan Kettering Cancer Center in New York.
For professionals
The study is special because it is the first randomized international trial for children with ALL receiving CAR T-cell treatment. Ten centers in Europe and the United States are collaborating in one joint research program. In total, the researchers hope to include approximately 120 to 130 children in the trial over the next two years.
‘Until now, research centers mainly investigated individually how CAR T-cell therapy could be further improved,’ says Calkoen. ‘It is powerful to now collaborate on one study with ten centers, even across the ocean. It’s only through collaboration that we can carry out a study like this.’